Pulmonary Hypertension Associated With Vitamin C Deficiency Is Rapidly Reversible

Tomás Woodgate1, Jay Patel2, Thomas Day3

  • 1National Paediatric Pulmonary Hypertension Service, Great Ormond Street Hospital, London.

Pediatrics
|March 16, 2026
PubMed

Insights

Severe pulmonary hypertension in children can be caused by vitamin C deficiency. Prompt vitamin C replacement therapy rapidly reverses this condition, highlighting the importance of nutritional assessment in pediatric cardiovascular health.

Area of Science:

  • Pediatric Cardiology
  • Nutritional Science
  • Radiology

Background:

  • Severe pulmonary hypertension (PH) in children is a critical condition.
  • Nutritional deficiencies, including vitamin C deficiency, can contribute to complex pediatric health issues.
  • Scurvy, a manifestation of severe vitamin C deficiency, can present with subtle radiographic findings.

Purpose of the Study:

  • To report a series of children with severe pulmonary hypertension linked to vitamin C deficiency.
  • To highlight the diagnostic clues and treatment response in these cases.
  • To emphasize the reversibility of PH associated with vitamin C deficiency.

Main Methods:

  • Case series of 4 children (aged 3-9 years) with severe PH.
  • Clinical presentation, echocardiography, N-terminal pro-B-type natriuretic peptide levels, and nutritional status assessment.
  • Radiologic review for subtle signs of scurvy.
  • Treatment with vitamin C replacement, with some receiving sildenafil concurrently.

Main Results:

  • All 4 children presented with severe PH, right ventricular dysfunction, and elevated NT-proBNP.
  • Musculoskeletal symptoms and peripheral edema were common presentations.
  • Subtle radiographic features of scurvy were noted in 2 patients.
  • Rapid clinical and echocardiographic improvement occurred within 3 months of vitamin C therapy.
  • One patient showed no response to sildenafil alone, responding only after vitamin C supplementation.

Conclusions:

  • Vitamin C deficiency is a potentially reversible cause of severe pulmonary hypertension in children.
  • Early recognition of nutritional deficiencies, including scurvy, is crucial for diagnosing PH.
  • Vitamin C replacement therapy is the primary treatment for PH associated with vitamin C deficiency.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
790
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
720
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
620
Vitamins01:30

Vitamins

Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced...
2.8K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
691
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
536